Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exclusive Remicade Contracts Are Slowing Biosimilar Uptake

Executive Summary

Exclusive contracts for J&J's Remicade have posed challenges for Pfizer's Inflectra in the commercial insurance market, the biosimilar's maker said during its second quarter earnings call.

You may also be interested in...



J&J’s Gorsky Hails Strong Performance By Immunology Therapies Tremfya, Stelara

A strong fourth quarter and full-year 2019 performance by J&J was driven by significant sales growth for Tremfya and Stelara. CFO Wolk said a $4bn opioids settlement remains on track.

Biocon Staying Firm On Insulins Path, Including Glargine

Biocon has reported strong second-quarter earnings and underscored its interest in the insulins space, including insulin glargine, at least for now. Merck & Co recently called off plans to commercialize its Lantus version.

Biocon Staying Firm On Insulins Path, Including Glargine

Biocon has reported strong second-quarter earnings and underscored its interest in the insulins space, including insulin glargine, at least for now. Merck & Co recently called off plans to commercialize its Lantus version.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL043097

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel